• Strafford #1Strafford will be offering a webinar/teleconference entitled "Lessons from PTAB Full or Partial Denials to Obtain a Denial and Avoid an IPR" on July 6, 2017 from 1:00 to 2:30 pm (EDT).  Thomas L. Irving, Joshua L. Goldberg, and Cory C. Bell of Finnegan Henderson Farabow Garrett & Dunner will provide patent counsel with an analysis of the ever-increasing number of Patent Trial and Appeal Board (PTAB) denials and partial denials and offer take-home lessons applicable in practitioners' daily practice.  The webinar will review the following topics:

    • How can practitioners use the lessons of the PTAB denials to learn what patent owners are doing to achieve their ultimate success: An IPR petition denial?
    • What can petitioners learn from the partially denied IPR institution decisions?
    • How can practitioners prosecute applications and claims to enhance likelihood of denial of IPRs and PGR petitions?

    The registration fee for the webinar is $297.  Those interested in registering for the webinar, can do so here.

  • By Paul Cole* —

    Federal Circuit SealProceedings for infringement of U.S. Patent No. 8,005,303 (Recognicorp, assigned from IQ Biometrix) resulted in an appeal decided on 28 April 2017, which decision was reviewed in this space by Michael Borella, and also criticised (see "Regnoicorp — A Miscarriage of Justice Calling for En Banc Reconsideration").

    As expected, a petition for en banc rehearing was filed on 30 May, and was followed on 11 June by an Independent Inventors' amicus brief, and on 13 June by a further amicus brief by the author.

    Recognicorp explained that encoding and decoding data using computers is an important and innovative field of technology and objected that the panel opinion threatened the validity of all encoding and decoding patents, including patents covering important technologies such as MP3 audio coding, MPEG video coding, JPEG image coding and encryption.  It cited decisions where such claims have been upheld including DDR Holdings, LLC v. Hotels.com; Cal. Inst. of Tech. v. Hughes Communs., Inc.; and TQP Dev and LLC v. Intuit Inc.

    Their brief identified at least two inventive concepts recited in the claims of the '303 patent:

    (1) using a single composite facial image code composed of a number of facial feature element codes, such as for lips or eyes, to represent the entire facial image instead of encoding the image pixel-by-pixel as was done in the prior art; and

    (2) using a particular algorithm to combine the various facial feature element codes together into a single composite facial image code by multiplying the facial code by a code factor for each facial feature.

    They argued that these qualified as improvements in technology or in a technical field.  There was no basis for holding that the fields of image encoding and data compression were not "technical field[s]" in which patentable improvements could be made, nor could reducing bandwidth and memory storage requirements be disregarded but instead enjoyed status as specific improvements in the functioning of a computer.  The improvements achieved here should be contrasted with Digitech where no improvement was asserted.

    Although the panel opinion objected that, like Digitech, "a user starts with data, codes that data using 'at least one multiplication operation,' and ends with a new form of data" Recognicorp replied that this was plainly not what the claims of the '303 patent recited.  They did not recite "start[ing] with data," or even "gathering . . . data [without] . . . input from a physical device," but rather began with "displaying facial feature images" which are "select[ed]" "via a user interface."  Similarly, the claims did not "end with a new form of data," but rather they ended with the display, on a second display, of the reproduction of a facial image based on the composite facial image code.  There was no basis for finding the claims ineligible under Alice step one merely because of the involvement of a mathematical method, compare MCro v Bandai, and also Enfish, which started with a mathematical table of rows and columns, performed mathematical operations and ended with a self-referential table for a computer database.

    In relation to the second step of Alice, it was argued that the panel wrongly rejected the potential that mathematical equations and algorithms, even when implemented on a computer to produce tangible benefits in that computer's operation, could constitute patentable inventive concepts.  The panel opinion failed to perform any such analysis — it did not attempt to analyze whether the "facial feature element codes," "code factors," and the "particular encoding process using the specific algorithm disclosed" that used those codes to create a "composite facial image code" was "significantly more" than "the abstract idea of encoding and decoding image data".  Recognicorp argued that improvements in computer and software technology often take the form of new and innovative mathematical operations and algorithms, which when appropriately claimed as being performed on a computer as part of a technological process, should be eligible for patent protection.

    The Individual Inventors' brief also took the position that the panel opinion had ignored the rule in Alice that eligibility under § 101 requires an analysis of all claim limitations as an ordered combination.  That rule had been clarified in McRO to require that all claim limitations be addressed in step 1 of the Alice test but had been discarded by the decision.  The wisdom "that courts 'must be careful to avoid oversimplifying the claims' by looking at them generally and failing to account for the specific requirements of the claims" stated in McRO had been ignored.  The consequence was that under the instant decision, patent examiners not only now have carte blanche to ignore any claim limitation and issue of evidence under step 1 of Alice, but are free to ignore decades of established precedential decisions focused on preemption in favor a per se rule having no basis in preemption.

    The Cole brief followed many of the arguments of Recognicorp and the Individual Inventors and asked:

    • What scope is attributable to the phrase "directed to" in the first stage of the Alice test, at what level of abstraction is interpretation of a representative claim impermissibly untethered from the express language of that claim, and is an abstraction permissible where it omits reference to elements positively recited in a representative claim?

    • Is a new and beneficial result improving a technological process available to rebut an objection that claimed subject matter falls within the law of nature, natural phenomenon or abstract idea exception?

    • Is the Alice test, as applied in the breadth of the present decision, incompatible with the obligations of the United States under Article 27 of TRIPS?

    In relation to the first question, the brief argued that the words "directed to" lack clear definition, which may account for the risk of inappropriate paraphrasing of specific and detailed claim language leading to unacceptable flexibility.  Arbitrary disregard of claimed elements when conducting the § 101 analysis creates uncertainty for patent applicants based both in the U.S. and in Europe, for those involved in re-examination and contentious proceedings before the USPTO and for those involved in litigation.  The solution is to reaffirm the rule accepted as black letter law that all elements or limitations recited in a claim must be taken into account when considering anticipation or infringement, and hence by implication § 101 eligibility (citing the case law listed in MPEP 2131 Anticipation), and that the arrangement of those elements specified in the claim must also be considered.

    Evidence of invention pertinent to § 103 should be equally applicable to § 101, and there was no evidence that the prior art paper strips nor the coding systems of Samuel Morse or Paul Revere can be said to beneficially improve the transmission of images.

    Finally, it argued that the present decision is in conflict with established legal principles under the EPC as exemplified in the landmark decision T 208/84 Computer-related invention/VICOM.  In that decision, the EPO held that a claim to digitally filtering a data array was an ineligible mathematical method, but it became eligible when explicitly applied to digitally processing images.  In contrast, the panel opinion here rejects operations performed on coded data as ineligible, but refuses to acknowledge that such operations should become eligible when applied to the production of images.

    It is to be hoped that the petition will be granted and that the present case will provide a landmark decision leading to a fairer and less arbitrary approach to eligibility both for computer-related inventions and for those such as Sequenom in life sciences.

    * Mr. Cole is a European Patent Attorney and Partner with Lucas & Co. in Warlingham, Surrey, UK and Visiting Professor at the Centre for Intellectual Property Policy & Management at Bournemouth University.

  • BIO, Biologics, and Biosimilars

    By Andrew Williams

    BIO International Convention_shortThe 2017 BIO International Convention began earlier this week, but there are still many sessions and forums still to come.  Patent Docs has been highlighting a few sessions or other opportunities, in thematic fashion, to help you navigate your way through the convention.  For example, today, we focus on sessions that will address the use of therapeutic biologics and the introduction of biosimilars.  Of course, Patent Docs authors and contributors will be present at BIO as part of the MBHB contingent, and Patent Docs readers are encouraged to stop by the MBHB booth (#1728) to discuss these sessions (or whatever other topic is of interest to you).

    One topic that is of particular interest to readers of this blog is that of the BPCIA and the introduction of biosimilars in the U.S. marketplace.  To address that interest, the Intellectual Property track will include a panel entitled "Biosimilars IP Litigation: Where We've Been and Where We're Heading," on Wednesday, June 21, 2017 at 3:00 PM.  Of course, the panel did not know the outcome of the Sandoz v. Amgen Supreme Court case when the description was written.  Nevertheless, litigation strategies that are likely to be implemented as a result of this case will certainly be discussed.  The panel promises to provide general guidance, general strategies, and general lessons learned from both sides of the issue.  Importantly, the various categories of patent claims being litigated will be discussed.  The panel will include the Hon. Faith Hochberg, United States District Judge (retired), and currently of Judge Hochberg ADR; Dr. Chuck Sholtz, Ph.D., Vice President, Intellectual Property at Coherus Biosciences; and Wendy Whiteford, Esq, BS, Vice President of Law at Amgen.  The session will be moderated by Mr. Bob Ramos, JD, MS, Partner at Procopio.

    There are, of course, topics outside of the Intellectual Property track dealing with the introduction and utilization of biologics.  For example, the Oncology Track will feature a session entitled "Immune-Oncology Drugs: Ready for First Line Therapy?" on Thursday, June 22, 2017 at 10:15 AM.  As the description points out, immune checkpoint inhibitors, such a Keytruda and Opdivo, have had remarkable success in the clinic.  The panel promises to look to whether the new immune-oncology ("IO") drugs are likely to supplant tumoricidal drugs and radiation as the first-line therapy for cancers.  The panel will address other questions such as:  Are IO drugs affordable?  Do biomarkers exist to identify and monitor patients?  Can IO drugs be combined with other IO or tumoricidal drugs to achieve maximum efficacy?  And, can the side effects be minimized?  The speakers on the panel will be Dr. Kaan Certal, Ph.D., head of external innovation, oncology for Sanofi U.S.; Dr. Norman Greenberg, Ph.D., Senior Vice President and Chief Scientific Officer for Atreca, Inc.; Kinney Horn, Director of Business Development at Genentech Inc.; and Tim Reilly, Vice President and Head of Oncology Early Asset Development at Bristol-Myers Squibb Company.  The session will be moderated by Dr. Tauseef Butt, Ph.D., President and CEO of Progenra Inc.

    One of the last events to address the issue of therapeutic biologics, among other things topics, will be The Scientific American WorldVIEW Super Session: Wrapping Up and Looking Forward, on Thursday, June 22, 2017 at 1:00 PM.  This session will include explore the multiplicity of issues raised during the week at BIO, and will create a snapshot of future trends.  The panel will also tackle the latest commercial, scientific, and ethical issues facing innovation stakeholders, both today and for the year ahead.  This is the 9th year that this Super Session will examine global life science innovation.  The panel will include, Lawrence Bloch, MD, JD, President of Infinity Pharmaceuticals; Donald Jones, Chief Digital Officer at Scripps Translational Science Institute; Dr. Kenneth Kizer, MD, MPH, Director at the Institute for Population Health Improvement, UC Davis Health; John Mendlein, Ph.D., JD, CEO and Director at aTYR Pharma; and Susan Peschin, MHS, President and CEO for Alliance for Aging Research.  This session will be moderated by Andrew Marshall, Chief Editor at Nature Biotechnology.

    We hope you have been, and will continue enjoying BIO 2017 for the upcoming few days.

  • BIO and the Microbiome

    By Andrew Williams

    BIO International Convention_shortThe 2017 BIO International Convention begins this week in San Diego.  This convention has become an important destination for all organizations working in the biotechnology space, but the large amount of information and opportunities available can appear daunting at first glance.  To assist our readers, we recently provided information about the convention, and listed sessions that might be of interest to Patent Docs readers (see "2017 BIO International Convention — Docs @ BIO").  In addition, with this post, we begin a more in-depth series of previews highlighting a few sessions or other opportunities, in thematic fashion, to help navigate the convention.  Of course, as we previously reported, Patent Docs authors and contributors will be present at BIO as part of the MBHB contingent.  Patent Docs readers are encouraged to stop by the MBHB booth (#1728) to discuss these sessions (or whatever other topics are of interest to you).

    The microbiome has been defined as the microorganisms in a particular environment, including the body or part of the body.  Recently, the topic of the microbiome has gained a lot of attention.  Indeed, over the past couple of years, Patent Docs has published a series of guest posts on the topic of the emergent microbiome, with one of the more recent posts appearing last February (see "The Emergent Microbiome: A Revolution for the Life Sciences — Part X, The Big Data Component").  It is no surprise, therefore, to find several educational sessions at BIO addressing the topic from various perspectives.

    The Intellectual Property track will feature a session on June 20, 2017 at 1:45 PM entitled "Innovation and the Human Microbiome: Patent Eligibility and IP Protection."  The description of the session notes that microbiome research is resulting in new diagnosis, therapies, and product development, but the related commercialization is creating IP challenges.  Because microbiomic inventions relate to microbes, microbial components, and microbial products, they could be susceptible to concerns of subject-matter eligibility stemming from recent decisions of the U.S. Supreme Court and the Federal Circuit, and guidelines from Patent Office.  Not only that, but the regulatory environment creates additional complexity as governments grapple with questions surrounding labeling and regulation of probiotics.  The session promises that attendees will hear about creative patent drafting, trademark rights, and contractual provisions that can be used to protect such innovations.  The speakers on the panel will be Amanda Barry, Associate General Counsel for Global Home Care and NA Fabric Care Innovation at The Procter & Gamble Company, Michelle Booden, Director of Intellectual Property and Licensing for Salk Institute for Biological Studies, and Simon O' Brian, Partner with D Young & Co LLP.  The session will be moderated by David Gass of Marshall Gerstein & Borun LLP.

    The microbiome focuses on the microorganisms found in the body (or parts of the body), but there is a new wave of discovery using pharmaceuticals to regulate the dialogue between microbiome and host.  The Next Generation Biotherapeutics track will feature this emerging area on June 21, 2017 at 4:15 PM in a session entitled "Microbiome 2.0: Going Beyond Bugs as Drugs."  The description notes that these new discoveries hold promise for many key areas, including insomnia, diabetes, and autism.  The panel will share insights into the following questions: what are the hottest new microbiome drug targets and why; what are the new approaches to regulate the gut-brain axis, and how does big data fit in?  The panel includes Dr. Tom Hallam, Ph.D., CEO of Leading BioSciences; Glenn Nedwin, Ph.D, President and CEP of Second Genome; Scott Peterson, Professor at Sanford Burnham Prebys Medical Discovery Institute; and Stephanie Robertson, Sr. Director, Consumer Science Innovation at Johnson & Johnson Innovation, California.  The panel will be moderated by Larry Smarr, Ph.D., Principal Investigator at the California Institute for Telecommunications and Information Technology.

    There will also be a session on June 21, 2017 at 3:00 PM entitled "Technologies for a Sustainable Future: Leveraging One Health and Engineering Synergies."  The panel for this session promises to explore emerging topics such as synthetic biology and the microbiome as examples of the important connections between challenges in the food systems and human health.  These challenges can lead to complex relationships across disciplines to enable sustainable solutions for health and wellness.  The panel will discuss ways in which "One Health and Engineering Synergies" can be leveraged to accelerate cutting edge research, created novel technologies, and develop tractable solutions.  This panel includes Joerg Bauer, Head of Scouting and Insight, Bioscience Research for BASF; David Kyle, Ph.D., CEO and Executive Director for Evolve Biosystems.  The panel will be moderated by Dushyant Pathak, Ph.D., MBA, Associate Vice Chancellor of Research for Technology Management & Corporate Relations, and Executive Director of Venture Catalyst at the University of California, Davis.

    Please be on the look-out for future preview posts, and we look forward to seeing you this week at BIO 2017.

  • CalendarJune 19-22, 2017 – BIO International Convention (Biotechnology Innovation Organization) – San Diego, CA

    June 22, 2017 – "Conflicts in Patent Prosecution: Avoiding the Ethical Pitfalls — Minimizing Risks of Malpractice Liability and Ethics Sanctions" (Strafford) – 1:00 to 2:30 pm (EDT)

    June 22, 2017 – "Who Owns the World's Patents?" (CPA Global) – beginning at 11:00 am (EST)

    June 27, 2017 – "CRISPR Confusion: A Legal and Practical Analysis for IP Professionals" (Technology Transfer Tactics) – 1:00 to 2:00 pm (Eastern)

    June 29, 2017 – Judicial Conference (U.S. Patent and Trademark Office Patent Trial and Appeal Board) – 1:00 to 5:00 pm (ET) – Alexandria, VA

    June 29, 2017 – "Section 102 and Prior Art: Navigating the Expanded Scope of Prior Art and AIA Exceptions" (Strafford) – 1:00 to 3:30 pm (EDT)

    June 29, 2017 – "Patent Eligibility Determination in a Post-Alice World: Significant Updates & Developments" (The Knowledge Group) – 12:00 to 1:30 pm (EST)

    August 10-11, 2017 – Advanced Patent Law Seminar (Chisum Patent Academy) – Seattle, WA

    August 14-15, 2017 – Advanced Patent Law Seminar (Chisum Patent Academy) – Seattle, WA

    ***Patent Docs is a media partner of this conference or CLE

  • USPTO SealThe U.S. Patent and Trademark Office Patent Trial and Appeal Board will be hosting Judicial Conference on June 29, 2017 from 1:00 to 5:00 pm (ET) in the Madison Auditorium on the USPTO campus in Alexandria, VA.  The program is intended to educate the public about aspects of Board practice and provide a forum to enhance the dialogue between the public and the Board.  The Conference will offer presentations on the following topics:

    • State of the Board
    • Behind the Scenes at PTAB: A Look at the Inner Workings
    • Perspectives from the Bench and Bar: Winning your Ex Parte Appeal
    • AIA Trial Hot Topics

    Following the Conference, an informal social gathering will be held a few blocks from the USPTO campus.

    There is no cost to attend and registration is not required.  The Conference will be webcast; instructions for viewing the webcast can be found here.  Additional information regarding the Conference can be found here.

  • Technology Transfer Tactics will be offering a webinar entitled "CRISPR Confusion: A Legal and Practical Analysis for IP Professionals" on June 27, 2017 from 1:00 to 2:00 pm (Eastern).  Patents Docs author Kevin E. Noonan of McDonnell Boehnen Hulbert & Berghoff LLP will cover the following topics:

    • A brief overview of the technology
    • A review of the patent positions of the parties
    • A discussion of the arguments raised in the Interference
    • An assessment of the PTAB's decision and its effect on the patents and applications
    • Analysis of strategies for further appeal
    • Impact on patent practice — claim strategy
    • Impact on licensing
    • Predictions regarding the patent and licensing landscape if the parties do not settle
    • Likelihoods and advantages of settlement

    The registration fee for the webinar is $197.  Those interested in registering for the webinar, can do so here.

    Technology Transfer Tactics

  • Strafford #1Strafford will be offering a webinar/teleconference entitled "Section 102 and Prior Art: Navigating the Expanded Scope of Prior Art and AIA Exceptions" on June 29, 2017 from 1:00 to 3:30 pm (EDT).  Anthony D. Del Monaco, Doris Johnson Hines, Thomas L. Irving of Finnegan Henderson Farabow Garrett & Dunner will examine AIA Section 102 prior art and the AIA exceptions, and offer best practices for identifying applicable prior art when filing or challenging patent applications, and making the correct choice of law for prosecuting.  The webinar will review the following topics:

    • How did AIA expand the definition of prior art?
    • What are the Section 102 exceptions and what is the impact on Section 103 art?
    • How can counsel claim—or defend against—post-AIA patent applications asserting priority over pre-AIA applications?
    • What practices should patent counsel employ in order to utilize prior art?

    The registration fee for the webinar is $447.  Those interested in registering for the webinar, can do so here.

  • The Knowledge GroupThe Knowledge Group will offer a live webcast entitled "Patent Eligibility Determination in a Post-Alice World: Significant Updates & Developments" on June 29, 2017 from 12:00 to 1:30 pm (EST).  Orlando Lopez of Burns & Levinson LLP, James J. DeCarlo of Greenberg Traurig, and Lewis E. Hudnell, III of Hudnell Law Group PC will present and analyze the recent trends and developments surrounding patent eligibility determinations since the Supreme Court's decision in Alice v. CLS Bank, and provide practitioners practical advice in traversing Alice challenges, in both prosecution and litigation.  The panel will cover the following topics:

    • Recent Developments in Case Law and at the PTO
    • Litigation and Prosecution Perspectives
    • Practitioner Roadmaps
    • Opportunities and Challenges

    Those interested in registering for the webinar can do so here.

  • CPA GlobalCPA Global will hosting a webinar entitled "Who Owns the World's Patents?" on June 22, 2017 beginning at 11:00 am (EST).  The webinar will offer a debate from Microsoft, Cravath Swaine & Moore LLP, and board members from ORoPO™ (Open Register of Patent Ownership) regarding patent ownership.  ORoPO was launched in June 2015 by organizations seeking to achieve greater transparency around patent ownership on a global scale.  ORoPO provides an open data register of patents, accessible to all at no cost.

    Those interested in registering for the webinar can do so here.